Ostojić, Marija

Link to this page

Authority KeyName Variants
ac9f1df2-92fd-4436-b777-9f44db667592
  • Ostojić, Marija (3)
Projects

Author's Bibliography

Rilmenidine binds to and inhibits the activity of MDR pumps in pancreatic ductal adenocarcinoma

Ostojić, Marija; Đurić, Ana; Srdić-Rajić, Tatjana; Dobričić, Vladimir; Grahovac, Jelena

(COST Action 17104 (STRATAGEM), 2022)

TY  - CONF
AU  - Ostojić, Marija
AU  - Đurić, Ana
AU  - Srdić-Rajić, Tatjana
AU  - Dobričić, Vladimir
AU  - Grahovac, Jelena
PY  - 2022
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/5477
AB  - Pancreatic ductal adenocarcinoma (PDAC) is the sixth leading cause of death worldwide and the fourth
in Europe with a 5-year survival rate. The common cause of treatment failure in PDAC patients is
multidrug resistance (MDR) due to the increased expression of plasma membrane efflux pumps that
limit the intracellular uptake and retention of numerous xeno- and endobiotics. As the 93.3% of
pancreatic carcinomas expressed P-glycoprotein (P-gp-MDR1/ABCB1) and 31% co-expressed multidrug
resistance protein 1 (MRP1/ABCC1) with MDR1 P-gp, the inhibition of these pumps may be the target
for novel anticancer drugs.
We used the FRED 3.2.0.2 software to predict the affinity of I1-imidazoline receptor ligand rilmenidine
within the binding site of P-gp-MDR1/ABCB1 and MRP1/ABCC1, and flow cytometry to evaluate the
effect of rilmenidine phosphate and rilmenidine fumarate on the efflux pumps in PDAC cells in vitro.
The results of the molecular docking studies indicate that rilmenidine has the binding affinity for both
P-gp-MDR1/ABCB1 and MRP1/ABCC1 efflux pumps. While, in vitro studies show that rilmenidine
fumarate has better potential to inhibit Calcein AM efflux than rilmenidine phosphate, and it did so in a
dose-dependent manner.
Our results indicate that rilmenidine has the affinity to bind to MDR efflux pumps and to inhibit their
activity. This potential of rilmenidine to overcome multidrug resistance in PDAC should be further
investigated in order to develop more effective PDAC therapy.
PB  - COST Action 17104 (STRATAGEM)
C3  - STRATAGEM CA17104, New Diagnostic and Therapeutic Tools against Multidrug Resistant Tumors, 5th Annual Meeting, 29th June - 1st July 2022, Coimbra, Portugal
T1  - Rilmenidine binds to and inhibits the activity of MDR pumps in pancreatic ductal adenocarcinoma
SP  - 80
EP  - 80
UR  - https://hdl.handle.net/21.15107/rcub_farfar_5477
ER  - 
@conference{
author = "Ostojić, Marija and Đurić, Ana and Srdić-Rajić, Tatjana and Dobričić, Vladimir and Grahovac, Jelena",
year = "2022",
abstract = "Pancreatic ductal adenocarcinoma (PDAC) is the sixth leading cause of death worldwide and the fourth
in Europe with a 5-year survival rate. The common cause of treatment failure in PDAC patients is
multidrug resistance (MDR) due to the increased expression of plasma membrane efflux pumps that
limit the intracellular uptake and retention of numerous xeno- and endobiotics. As the 93.3% of
pancreatic carcinomas expressed P-glycoprotein (P-gp-MDR1/ABCB1) and 31% co-expressed multidrug
resistance protein 1 (MRP1/ABCC1) with MDR1 P-gp, the inhibition of these pumps may be the target
for novel anticancer drugs.
We used the FRED 3.2.0.2 software to predict the affinity of I1-imidazoline receptor ligand rilmenidine
within the binding site of P-gp-MDR1/ABCB1 and MRP1/ABCC1, and flow cytometry to evaluate the
effect of rilmenidine phosphate and rilmenidine fumarate on the efflux pumps in PDAC cells in vitro.
The results of the molecular docking studies indicate that rilmenidine has the binding affinity for both
P-gp-MDR1/ABCB1 and MRP1/ABCC1 efflux pumps. While, in vitro studies show that rilmenidine
fumarate has better potential to inhibit Calcein AM efflux than rilmenidine phosphate, and it did so in a
dose-dependent manner.
Our results indicate that rilmenidine has the affinity to bind to MDR efflux pumps and to inhibit their
activity. This potential of rilmenidine to overcome multidrug resistance in PDAC should be further
investigated in order to develop more effective PDAC therapy.",
publisher = "COST Action 17104 (STRATAGEM)",
journal = "STRATAGEM CA17104, New Diagnostic and Therapeutic Tools against Multidrug Resistant Tumors, 5th Annual Meeting, 29th June - 1st July 2022, Coimbra, Portugal",
title = "Rilmenidine binds to and inhibits the activity of MDR pumps in pancreatic ductal adenocarcinoma",
pages = "80-80",
url = "https://hdl.handle.net/21.15107/rcub_farfar_5477"
}
Ostojić, M., Đurić, A., Srdić-Rajić, T., Dobričić, V.,& Grahovac, J.. (2022). Rilmenidine binds to and inhibits the activity of MDR pumps in pancreatic ductal adenocarcinoma. in STRATAGEM CA17104, New Diagnostic and Therapeutic Tools against Multidrug Resistant Tumors, 5th Annual Meeting, 29th June - 1st July 2022, Coimbra, Portugal
COST Action 17104 (STRATAGEM)., 80-80.
https://hdl.handle.net/21.15107/rcub_farfar_5477
Ostojić M, Đurić A, Srdić-Rajić T, Dobričić V, Grahovac J. Rilmenidine binds to and inhibits the activity of MDR pumps in pancreatic ductal adenocarcinoma. in STRATAGEM CA17104, New Diagnostic and Therapeutic Tools against Multidrug Resistant Tumors, 5th Annual Meeting, 29th June - 1st July 2022, Coimbra, Portugal. 2022;:80-80.
https://hdl.handle.net/21.15107/rcub_farfar_5477 .
Ostojić, Marija, Đurić, Ana, Srdić-Rajić, Tatjana, Dobričić, Vladimir, Grahovac, Jelena, "Rilmenidine binds to and inhibits the activity of MDR pumps in pancreatic ductal adenocarcinoma" in STRATAGEM CA17104, New Diagnostic and Therapeutic Tools against Multidrug Resistant Tumors, 5th Annual Meeting, 29th June - 1st July 2022, Coimbra, Portugal (2022):80-80,
https://hdl.handle.net/21.15107/rcub_farfar_5477 .

Metabolic and inflammatory homeostasis disorders in the pathogenesis of colorectal cancer

Mihajlović, Marija; Ninić, Ana; Ostojić, Marija; Sopić, Miron; Stefanović, Aleksandra; Vekić, Jelena; Antonić, Tamara; Spasojević-Kalimanovska, Vesna; Bogavac-Stanojević, Nataša; Zeljković, Aleksandra

(Savez farmaceutskih udruženja Srbije (SFUS), 2022)

TY  - CONF
AU  - Mihajlović, Marija
AU  - Ninić, Ana
AU  - Ostojić, Marija
AU  - Sopić, Miron
AU  - Stefanović, Aleksandra
AU  - Vekić, Jelena
AU  - Antonić, Tamara
AU  - Spasojević-Kalimanovska, Vesna
AU  - Bogavac-Stanojević, Nataša
AU  - Zeljković, Aleksandra
PY  - 2022
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/4645
AB  - In order to understand the metabolic and immune potential of adiponectin in
colorectal cancer (CRC), attention is drawn to its receptors: adiponectin receptor 1
(ADIPOR1) and adiponectin receptor 2 (ADIPOR2). Gene set enrichment analysis (GSEA) of
datasets based on malignant tissue samples and peripheral blood monocytes (PBMs) was
used to explore mRNA fingerprints of different signaling pathways best associated with
ADIPOR1/ADIPOR2 gene expression levels. Transcriptomic datasets GSE44076 (1) and
GSE47756 (2) were downloaded from the NCBI Gene Expression Omnibus database. In the
GSE44076 dataset, three groups were formed: 98 colon tumor tissue and matched tumor-
adjacent mucosa samples and tissue samples from 50 healthy volunteers. The other set
(GSE47756) contained information on PBMs' gene signature in CRC, by forming two groups:
38 samples from healthy subjects and 55 CRC patients. GSEA analysis of the GSE44076
dataset implied that ADIPOR1 mRNA levels were in negative association with MTORC1 and
TNF-α NF-κB signaling pathways in tumor tissue. At the same time, ADIPOR2 was positively
associated with metabolic gene sets such as cholesterol homeostasis, glycolysis and PPAR
signaling. Quite opposite to the GSE44076 dataset, GSEA analysisis of GSE47756 revealed
that ADIPOR1 was a metabolically active receptor in PBMs of CRC patients. Surprisingly, the
TNF-α NF-κB signaling pathway gene sets were positively associated with ADIPOR1 mRNA
levels in monocytes of the cancer group. Different types of metabolic and immune regulation
achieved through ADIPOR1/ADIPOR2 in tumor and PBMs suggest possible novel therapeutic
targets in CRC.
AB  - Da bi se razumeo metabolički i imuni potencijal adiponektina u kolorektalnom
karcinomu (CRC), pažnja se mora obratiti i na njegove receptore: adiponektinski receptor 1
(ADIPOR1) i adiponektinski receptor 2 (ADIPOR2). Gene set enrichment analiza (GSEA) dva
skupa podataka, zasnovanih na uzorcima malignog tkiva i na monocitima periferne krvi
(PBM) je korišćena da bi se obezbedili genetski otisci različitih signalnih puteva koji su bili
najbolje povezani sa ekspresijom gena ADIPOR1/ADIPOR2. Skupovi transkriptomskih
podataka GSE44076 (1) i GSE47756 (2) su preuzeti iz NCBI Gene Expression Omnibus baze
podataka. U skupu podataka GSE44076 formirane su tri grupe: 98 uparenih uzoraka
tumorskog tkiva debelog creva i susedne mukoze i uzorci tkiva 50 zdravih dobrovoljaca.
Drugi set (GSE47756) je sadržao informacije o otisku gena PBM u CRC sa formiranim dvema
grupama: 38 uzoraka zdravih subjekata i 55 pacijenata sa CRC. GSEA analiza skupa podataka
GSE44076 je implicira da su nivoi iRNK ADIPOR1 negativno korelirali sa MTORC1 i TNF-α
NF-κB signalnim putevima u tumorskom tkivu. Istovremeno, ADIPOR2 je bio pozitivno
povezan sa skupovima gena metaboličkih puteva kao što su homeostaza holesterola,
glikoliza i PPAR signalizacija. Nasuprot GSE44076 skupu podataka, GSEA analiza GSE47756
transkriptomskog seta je otkrila da je ADIPOR1 zapravo metabolički aktivan receptor u PBM
pacijenata sa CRC. Iznenađujuć e, setovi gena koji su se odnosili na signalni put TNF-α NF-κB
su bili pozitivno povezani sa nivoima iRNK ADIPOR1 u monocitima grupe sa karcinomom.
Različite vrste metaboličke i imune regulacije koje se postižu preko ADIPOR1/ADIPOR2 u
tumoru i PBM sugerišu moguć e nove terapeutske ciljeve u CRC.
PB  - Savez farmaceutskih udruženja Srbije (SFUS)
C3  - Arhiv za farmaciju
T1  - Metabolic and inflammatory homeostasis disorders in the pathogenesis of colorectal cancer
T1  - Poremećaji metaboličke i inflamatorne homeostaze u patogenezi kolorektalnog karcinoma
VL  - 72
IS  - 4 suplement
SP  - S622
EP  - S623
UR  - https://hdl.handle.net/21.15107/rcub_farfar_4645
ER  - 
@conference{
author = "Mihajlović, Marija and Ninić, Ana and Ostojić, Marija and Sopić, Miron and Stefanović, Aleksandra and Vekić, Jelena and Antonić, Tamara and Spasojević-Kalimanovska, Vesna and Bogavac-Stanojević, Nataša and Zeljković, Aleksandra",
year = "2022",
abstract = "In order to understand the metabolic and immune potential of adiponectin in
colorectal cancer (CRC), attention is drawn to its receptors: adiponectin receptor 1
(ADIPOR1) and adiponectin receptor 2 (ADIPOR2). Gene set enrichment analysis (GSEA) of
datasets based on malignant tissue samples and peripheral blood monocytes (PBMs) was
used to explore mRNA fingerprints of different signaling pathways best associated with
ADIPOR1/ADIPOR2 gene expression levels. Transcriptomic datasets GSE44076 (1) and
GSE47756 (2) were downloaded from the NCBI Gene Expression Omnibus database. In the
GSE44076 dataset, three groups were formed: 98 colon tumor tissue and matched tumor-
adjacent mucosa samples and tissue samples from 50 healthy volunteers. The other set
(GSE47756) contained information on PBMs' gene signature in CRC, by forming two groups:
38 samples from healthy subjects and 55 CRC patients. GSEA analysis of the GSE44076
dataset implied that ADIPOR1 mRNA levels were in negative association with MTORC1 and
TNF-α NF-κB signaling pathways in tumor tissue. At the same time, ADIPOR2 was positively
associated with metabolic gene sets such as cholesterol homeostasis, glycolysis and PPAR
signaling. Quite opposite to the GSE44076 dataset, GSEA analysisis of GSE47756 revealed
that ADIPOR1 was a metabolically active receptor in PBMs of CRC patients. Surprisingly, the
TNF-α NF-κB signaling pathway gene sets were positively associated with ADIPOR1 mRNA
levels in monocytes of the cancer group. Different types of metabolic and immune regulation
achieved through ADIPOR1/ADIPOR2 in tumor and PBMs suggest possible novel therapeutic
targets in CRC., Da bi se razumeo metabolički i imuni potencijal adiponektina u kolorektalnom
karcinomu (CRC), pažnja se mora obratiti i na njegove receptore: adiponektinski receptor 1
(ADIPOR1) i adiponektinski receptor 2 (ADIPOR2). Gene set enrichment analiza (GSEA) dva
skupa podataka, zasnovanih na uzorcima malignog tkiva i na monocitima periferne krvi
(PBM) je korišćena da bi se obezbedili genetski otisci različitih signalnih puteva koji su bili
najbolje povezani sa ekspresijom gena ADIPOR1/ADIPOR2. Skupovi transkriptomskih
podataka GSE44076 (1) i GSE47756 (2) su preuzeti iz NCBI Gene Expression Omnibus baze
podataka. U skupu podataka GSE44076 formirane su tri grupe: 98 uparenih uzoraka
tumorskog tkiva debelog creva i susedne mukoze i uzorci tkiva 50 zdravih dobrovoljaca.
Drugi set (GSE47756) je sadržao informacije o otisku gena PBM u CRC sa formiranim dvema
grupama: 38 uzoraka zdravih subjekata i 55 pacijenata sa CRC. GSEA analiza skupa podataka
GSE44076 je implicira da su nivoi iRNK ADIPOR1 negativno korelirali sa MTORC1 i TNF-α
NF-κB signalnim putevima u tumorskom tkivu. Istovremeno, ADIPOR2 je bio pozitivno
povezan sa skupovima gena metaboličkih puteva kao što su homeostaza holesterola,
glikoliza i PPAR signalizacija. Nasuprot GSE44076 skupu podataka, GSEA analiza GSE47756
transkriptomskog seta je otkrila da je ADIPOR1 zapravo metabolički aktivan receptor u PBM
pacijenata sa CRC. Iznenađujuć e, setovi gena koji su se odnosili na signalni put TNF-α NF-κB
su bili pozitivno povezani sa nivoima iRNK ADIPOR1 u monocitima grupe sa karcinomom.
Različite vrste metaboličke i imune regulacije koje se postižu preko ADIPOR1/ADIPOR2 u
tumoru i PBM sugerišu moguć e nove terapeutske ciljeve u CRC.",
publisher = "Savez farmaceutskih udruženja Srbije (SFUS)",
journal = "Arhiv za farmaciju",
title = "Metabolic and inflammatory homeostasis disorders in the pathogenesis of colorectal cancer, Poremećaji metaboličke i inflamatorne homeostaze u patogenezi kolorektalnog karcinoma",
volume = "72",
number = "4 suplement",
pages = "S622-S623",
url = "https://hdl.handle.net/21.15107/rcub_farfar_4645"
}
Mihajlović, M., Ninić, A., Ostojić, M., Sopić, M., Stefanović, A., Vekić, J., Antonić, T., Spasojević-Kalimanovska, V., Bogavac-Stanojević, N.,& Zeljković, A.. (2022). Metabolic and inflammatory homeostasis disorders in the pathogenesis of colorectal cancer. in Arhiv za farmaciju
Savez farmaceutskih udruženja Srbije (SFUS)., 72(4 suplement), S622-S623.
https://hdl.handle.net/21.15107/rcub_farfar_4645
Mihajlović M, Ninić A, Ostojić M, Sopić M, Stefanović A, Vekić J, Antonić T, Spasojević-Kalimanovska V, Bogavac-Stanojević N, Zeljković A. Metabolic and inflammatory homeostasis disorders in the pathogenesis of colorectal cancer. in Arhiv za farmaciju. 2022;72(4 suplement):S622-S623.
https://hdl.handle.net/21.15107/rcub_farfar_4645 .
Mihajlović, Marija, Ninić, Ana, Ostojić, Marija, Sopić, Miron, Stefanović, Aleksandra, Vekić, Jelena, Antonić, Tamara, Spasojević-Kalimanovska, Vesna, Bogavac-Stanojević, Nataša, Zeljković, Aleksandra, "Metabolic and inflammatory homeostasis disorders in the pathogenesis of colorectal cancer" in Arhiv za farmaciju, 72, no. 4 suplement (2022):S622-S623,
https://hdl.handle.net/21.15107/rcub_farfar_4645 .

Association of Adiponectin Receptors with Metabolic and Immune Homeostasis Parameters in Colorectal Cancer: In Silico Analysis and Observational Findings

Mihajlović, Marija; Ninić, Ana; Ostojić, Marija; Sopić, Miron; Stefanović, Aleksandra; Vekić, Jelena; Antonić, Tamara; Zeljković, Dejan; Trifunović, Branislav; Spasojević-Kalimanovska, Vesna; Bogavac-Stanojević, Nataša; Jančić, Ivan; Zeljković, Aleksandra

(MDPI, 2022)

TY  - JOUR
AU  - Mihajlović, Marija
AU  - Ninić, Ana
AU  - Ostojić, Marija
AU  - Sopić, Miron
AU  - Stefanović, Aleksandra
AU  - Vekić, Jelena
AU  - Antonić, Tamara
AU  - Zeljković, Dejan
AU  - Trifunović, Branislav
AU  - Spasojević-Kalimanovska, Vesna
AU  - Bogavac-Stanojević, Nataša
AU  - Jančić, Ivan
AU  - Zeljković, Aleksandra
PY  - 2022
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/4327
AB  - Adiponectin (ADIPOQ) as both a regulator of metabolic homeostasis and a protein involved in immune response might be of particular interest to contemporary laboratory medicine, especially in terms of minimally invasive diagnostics. The diverse roles of ADIPOQ with regard to the immune and metabolic aspects of colorectal carcinogenesis have been proposed. However, the expression of its receptors ADIPOR1 and ADIPOR2 is scarcely explored in peripheral blood mononuclear cells (PBMCs). Moreover, ADIPORs’ relationships with the immune response mediator TNF-α have not been previously investigated in the PBMCs of CRC patients. This study used both in silico and observational case–control analyses with the aim of exploring the association of ADIPOR gene expression and ADIPOQ single nucleotide polymorphisms (SNPs) with the inflammatory marker TNF-α and lipid status parameters in patients with CRC. Publicly available transcriptomic datasets (GSE47756, GSE44076) obtained from analyses of monocytes and CRC tissue samples were employed for the in silico evaluation of ADIPORs’ specific genetic traits. GSE47756 and GSE44076 datasets were processed with GSEA software to provide a genetic fingertip of different signaling pathways associated with ADIPORs’ mRNA levels. The case–control aspect of the study included the PBMC samples of 73 patients diagnosed with CRC and 80 healthy volunteers. The PCR method was carried out for the PBMC gene expression analysis (ADIPOR1, ADIPOR2, TNF-α mRNA levels) and for the subjects’ genotyping (ADIPOQ rs266729, ADIPOR1 rs7539542). GSEA showed significant associations of ADIPOR mRNA expression with gene sets related to metabolic and immune homeostasis in both datasets. The case–control study revealed the association of ADIPOR1 rs7539542 with reduced lipid status parameters in CRC. In addition, PBMC ADIPOR1 mRNA levels decreased in CRC (p < 0.001), whereas ADIPOR2 mRNA did not differ between the groups (p = 0.442). A reduction in PBMC TNF-α mRNA levels was noted in CRC (p < 0.05). Our results indicate that ADIPOR1 and ADIPOR2 play a significant role in the alteration of both metabolic and immune homeostasis during the progression of CRC. For the first time, ADIPOR1 is shown to be a specific receptor for mediating ADIPOQ’s effects in the PBMCs of CRC patients.
PB  - MDPI
T2  - International Journal of Environmental Research and Public Health
T1  - Association of Adiponectin Receptors with Metabolic and Immune Homeostasis Parameters in Colorectal Cancer: In Silico Analysis and Observational Findings
VL  - 19
IS  - 22
DO  - 10.3390/ijerph192214995
ER  - 
@article{
author = "Mihajlović, Marija and Ninić, Ana and Ostojić, Marija and Sopić, Miron and Stefanović, Aleksandra and Vekić, Jelena and Antonić, Tamara and Zeljković, Dejan and Trifunović, Branislav and Spasojević-Kalimanovska, Vesna and Bogavac-Stanojević, Nataša and Jančić, Ivan and Zeljković, Aleksandra",
year = "2022",
abstract = "Adiponectin (ADIPOQ) as both a regulator of metabolic homeostasis and a protein involved in immune response might be of particular interest to contemporary laboratory medicine, especially in terms of minimally invasive diagnostics. The diverse roles of ADIPOQ with regard to the immune and metabolic aspects of colorectal carcinogenesis have been proposed. However, the expression of its receptors ADIPOR1 and ADIPOR2 is scarcely explored in peripheral blood mononuclear cells (PBMCs). Moreover, ADIPORs’ relationships with the immune response mediator TNF-α have not been previously investigated in the PBMCs of CRC patients. This study used both in silico and observational case–control analyses with the aim of exploring the association of ADIPOR gene expression and ADIPOQ single nucleotide polymorphisms (SNPs) with the inflammatory marker TNF-α and lipid status parameters in patients with CRC. Publicly available transcriptomic datasets (GSE47756, GSE44076) obtained from analyses of monocytes and CRC tissue samples were employed for the in silico evaluation of ADIPORs’ specific genetic traits. GSE47756 and GSE44076 datasets were processed with GSEA software to provide a genetic fingertip of different signaling pathways associated with ADIPORs’ mRNA levels. The case–control aspect of the study included the PBMC samples of 73 patients diagnosed with CRC and 80 healthy volunteers. The PCR method was carried out for the PBMC gene expression analysis (ADIPOR1, ADIPOR2, TNF-α mRNA levels) and for the subjects’ genotyping (ADIPOQ rs266729, ADIPOR1 rs7539542). GSEA showed significant associations of ADIPOR mRNA expression with gene sets related to metabolic and immune homeostasis in both datasets. The case–control study revealed the association of ADIPOR1 rs7539542 with reduced lipid status parameters in CRC. In addition, PBMC ADIPOR1 mRNA levels decreased in CRC (p < 0.001), whereas ADIPOR2 mRNA did not differ between the groups (p = 0.442). A reduction in PBMC TNF-α mRNA levels was noted in CRC (p < 0.05). Our results indicate that ADIPOR1 and ADIPOR2 play a significant role in the alteration of both metabolic and immune homeostasis during the progression of CRC. For the first time, ADIPOR1 is shown to be a specific receptor for mediating ADIPOQ’s effects in the PBMCs of CRC patients.",
publisher = "MDPI",
journal = "International Journal of Environmental Research and Public Health",
title = "Association of Adiponectin Receptors with Metabolic and Immune Homeostasis Parameters in Colorectal Cancer: In Silico Analysis and Observational Findings",
volume = "19",
number = "22",
doi = "10.3390/ijerph192214995"
}
Mihajlović, M., Ninić, A., Ostojić, M., Sopić, M., Stefanović, A., Vekić, J., Antonić, T., Zeljković, D., Trifunović, B., Spasojević-Kalimanovska, V., Bogavac-Stanojević, N., Jančić, I.,& Zeljković, A.. (2022). Association of Adiponectin Receptors with Metabolic and Immune Homeostasis Parameters in Colorectal Cancer: In Silico Analysis and Observational Findings. in International Journal of Environmental Research and Public Health
MDPI., 19(22).
https://doi.org/10.3390/ijerph192214995
Mihajlović M, Ninić A, Ostojić M, Sopić M, Stefanović A, Vekić J, Antonić T, Zeljković D, Trifunović B, Spasojević-Kalimanovska V, Bogavac-Stanojević N, Jančić I, Zeljković A. Association of Adiponectin Receptors with Metabolic and Immune Homeostasis Parameters in Colorectal Cancer: In Silico Analysis and Observational Findings. in International Journal of Environmental Research and Public Health. 2022;19(22).
doi:10.3390/ijerph192214995 .
Mihajlović, Marija, Ninić, Ana, Ostojić, Marija, Sopić, Miron, Stefanović, Aleksandra, Vekić, Jelena, Antonić, Tamara, Zeljković, Dejan, Trifunović, Branislav, Spasojević-Kalimanovska, Vesna, Bogavac-Stanojević, Nataša, Jančić, Ivan, Zeljković, Aleksandra, "Association of Adiponectin Receptors with Metabolic and Immune Homeostasis Parameters in Colorectal Cancer: In Silico Analysis and Observational Findings" in International Journal of Environmental Research and Public Health, 19, no. 22 (2022),
https://doi.org/10.3390/ijerph192214995 . .
1
2
2